Artificial Intelligence Transforming Healthcare and Improving Lives
AI refers to computer systems capable of performing tasks that typically require human intelligence, such as learning, reasoning, pattern recognition, and decision-making. Within healthcare, AI draws upon vast medical datasets—ranging from electronic health records and genetic data to real-time wearable device streams—and applies sophisticated algorithms to uncover patterns, predict outcomes, and recommend optimal interventions. The goal is not to replace clinicians and caregivers but to amplify their abilities, reduce diagnostic errors, and enable personalized, efficient, and timely care.
One of the most transformative applications of AI in healthcare is in disease diagnosis, particularly using medical imaging. AI-powered tools can analyze X-rays, CT scans, MRIs, and retinal scans at incredible speeds and with accuracy levels that often match or surpass human experts. Advanced algorithms are trained on millions of medical images, allowing them to detect subtle changes in tissue and anatomical structures that indicate diseases such as: Cancer (breast, lung, skin, and prostate): AI can spot early tumor growths that radiologists might miss, aiding in earlier detection and better patient outcomes.
(breast, lung, skin, and prostate): AI can spot early tumor growths that radiologists might miss, aiding in earlier detection and better patient outcomes. Eye diseases : Diabetic retinopathy and age-related macular degeneration can be detected using AI analysis of retinal imagery, helping prevent blindness.
: Diabetic retinopathy and age-related macular degeneration can be detected using AI analysis of retinal imagery, helping prevent blindness. Neurological disorders: AI models detect anomalies in brain scans indicating conditions like epilepsy, stroke, and Alzheimer's far more quickly than standard methods.
Medical errors are a leading cause of preventable harm. By double-checking, highlighting anomalies, and flagging uncertain cases for further review, AI minimizes oversight. For example, a study showed that AI could detect breast cancer on mammograms with higher sensitivity and specificity than radiologists.
No two people are biologically identical. The same disease may progress differently among patients due to genetic, lifestyle, and environmental variations. AI plays a vital role in making precision medicine a reality—treatments are customized based on individual molecular profiles. By analyzing genomic data, AI predicts how a patient will respond to specific drugs, identifies genetic risks, and helps design gene therapies.
Continuous glucose monitoring systems empowered by AI adjust diabetes management in real time, analyzing dietary intake, exercise, and blood sugar trends to optimize insulin delivery. Similarly, wearable devices combined with AI alert heart failure patients before their condition worsens, enabling early intervention and reduction in hospitalizations.
Conventional drug discovery is costly and time-consuming. AI revolutionizes this process by: Screening millions of compounds for drug candidates at unprecedented speeds.
Predicting drug efficacy, optimal dosages, and potential side effects.
Personalizing drug combinations for individuals based on genetic makeup and disease behavior.
This accelerates the arrival of novel treatments and reduces costs, making medicine more accessible.
AI helps predict who is at risk of developing certain conditions (like diabetes, cardiovascular disease, or sepsis) by analyzing medical records, social determinants, and lifestyle data. Early identification allows for proactive interventions—ranging from lifestyle modifications to preemptive medication—which can delay or even prevent disease onset.
Hospital readmission within 30 days is costly for both patients and systems. Several health systems use AI algorithms to flag patients at high risk of readmission so care teams can intervene with additional monitoring, support, home visits, or telemedicine follow-ups.
AI can detect patterns in public health data, travel patterns, social media signals, and genomic sequencing of pathogens. This helps forecast infectious disease outbreaks (such as influenza, COVID-19, or Ebola), allowing leaders to pre-position resources and enforce public health policies quickly.
AI-driven chatbots and voice assistants operate around the clock, answering patient questions, managing appointments, providing medication reminders, and offering first-line triage advice. For individuals with chronic diseases, these tools check on symptoms daily, record vitals, and escalate issues to care teams when necessary.
Digital therapeutics use AI-powered mobile apps to deliver behavioral interventions, manage pain, encourage activity, and support mental health. For example, apps can coach users through exercises to relieve chronic pain, offer personalized cognitive behavioral therapy for anxiety and depression, or gamify medication adherence for children.
Wearables and home-based sensors collect data on heart rate, blood pressure, oxygen saturation, movement, and even sleep patterns. AI interprets this data, highlighting trends, and alerting caregivers early when intervention is needed, thus enabling proactive care outside the traditional clinic setting.
Healthcare systems face immense pressure to improve efficiency while maintaining quality. AI optimizes scheduling, resource allocation, and administrative workflows: Triage : AI-powered systems assist paramedics in determining the severity of ambulance cases and the most appropriate hospital destination, saving time and lives.
: AI-powered systems assist paramedics in determining the severity of ambulance cases and the most appropriate hospital destination, saving time and lives. Clinical documentation : Automated transcription and smart note-taking free up doctors from paperwork, allowing more focus on patient care.
: Automated transcription and smart note-taking free up doctors from paperwork, allowing more focus on patient care. Billing and claims: AI reviews insurance claims, identifying fraud, reducing errors, and speeding up reimbursement.
Clinical trials are expensive and often delayed due to challenges in site selection and patient recruitment. AI helps to: Identify optimal trial sites based on real-world data.
Match eligible and diverse participants, ensuring broader and more relevant trial results.
Predict and mitigate obstacles—such as withdrawals or protocol violations—by adapting recruitment and retention strategies in real time.
By shortening time-to-diagnosis, minimizing preventable admissions, and improving treatment efficacy, AI helps control rising healthcare expenditures. It also contributes to value-based care models by improving outcomes while using fewer resources.
AI-powered systems synthesize large volumes of medical literature, guidelines, and individual patient data to provide clinicians with evidence-based recommendations—helping them select the most effective therapies, avoid harmful drug interactions, and keep up with the ever-growing body of medical knowledge.
Virtual patients and intelligent simulation platforms powered by AI enhance medical training, allowing clinicians and students to practice complex scenarios and receive tailored feedback. AI also helps identify gaps in knowledge, guiding continuous professional development.
A significant proportion of the world's population lacks ready access to quality healthcare, often due to provider shortages, geographic barriers, or cost. AI is helping bridge this gap: Remote diagnostics : AI tools enable health workers in low-resource settings to screen for diseases with smartphone-based imaging and cloud analytics.
: AI tools enable health workers in low-resource settings to screen for diseases with smartphone-based imaging and cloud analytics. Automated translation : Multilingual AI models facilitate communication between patients and providers, breaking down language barriers.
: Multilingual AI models facilitate communication between patients and providers, breaking down language barriers. Telemedicine platforms: AI-driven services connect patients anywhere with specialists, extending high-level care to underserved areas.
The transformative promise of AI comes with substantial challenges:
AI depends on sensitive medical data. Ensuring this data is secure, anonymized, and used ethically is paramount. Health organizations must comply with strict privacy regulations and remain vigilant to cyber threats.
AI models can perpetuate existing health disparities if trained on unrepresentative data. Biases in algorithms may lead to worse outcomes for minority or marginalized populations. Ongoing efforts focus on transparent data collection, bias detection, and inclusive model development.
Clinicians might distrust or resist AI recommendations, especially if the system's reasoning is opaque ('black box' problem). To foster adoption, AI outputs must be explainable and integrated into clinical workflows.
AI-enabled devices and software require rigorous regulatory approval to ensure effectiveness and safety. Standards are still evolving, and regulatory bodies worldwide are updating frameworks to keep pace with AI innovation.
Google Health's AI model trained on mammograms achieved higher accuracy than radiologists in identifying breast tumors, reducing both false negatives and false positives. This has led to earlier interventions and potentially saved lives.
In India, AI-based retinal screening allows technicians to identify diabetic retinopathy in local clinics, referring only urgent cases to distant specialists. This has improved outcomes for thousands who previously lacked access to eye care.
AI-powered robots and digital companions provide reminders, monitor mood and safety, and offer social interaction for older adults. These systems, already in use in parts of Europe and Asia, reduce loneliness and delay the need for institutional care.
During the pandemic, AI helped accelerate vaccine development, optimize supply chains for personal protective equipment, track outbreaks, and inform public health decision-making by modeling possible scenarios.
The journey of AI in healthcare is just beginning. In the coming years, we can expect: Further integration of multi-modal data (genomic, clinical, imaging, behavioral, and social determinants) to enhance predictive power and personalize interventions.
Growing democratization of diagnostic and monitoring tools via smartphones and low-cost devices.
Real-time adaptive clinical guidelines—algorithms that continuously learn from new data, clinical outcomes, and real-world evidence.
Expansion of AI's reach into mental health, voice analysis for neurological and psychiatric disorders, and advanced prosthetics.
Closer collaboration between AI developers, clinicians, regulatory bodies, and patients to ensure AI tools are transparent, ethical, and trusted.
Artificial intelligence is not a panacea, but it is a catalyst—empowering clinicians, engaging patients, and optimizing the use of resources with the ultimate goal of better health for all. Responsible adoption and ongoing vigilance regarding ethics, equity, and privacy are essential to harness the benefits and minimize risks. As AI continues to evolve, its positive impact on the healthcare ecosystem will become ever more profound, bringing us closer to a future where health is more predictive, personalized, preventive, and accessible
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
Biogen BIIB will report second-quarter 2025 results on July 31, before market open. In the last reported quarter, the company's earnings missed expectation by 7.4%. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $2.32 billion and $3.95 per share, respectively. Factors to Consider for Biogen In the second quarter, lower sales of Biogen's multiple sclerosis ('MS') drugs are likely to have been offset by sequential revenue growth from new products. Sales of Biogen's MS drugs like Tecfidera and Tysabri are likely to have declined due to generic competition for Tecfidera globally and biosimilar competition to Tysabri in Europe and rising competitive pressure in the MS market. Biosimilar versions of Tysabri are expected to be launched in the United States in the fourth quarter of 2025. The Zacks Consensus Estimate and our model estimate for second-quarter sales of Tecfidera are pegged at $178.0 million and $173.9 million, respectively. The Zacks Consensus Estimate and our estimate for Tysabri are pegged at $373.0 million and $395.5 million, respectively. Sales of another MS drug Vumerity are expected to have risen due to higher demand. The Zacks Consensus Estimate and our estimate for Vumerity are pegged at $70.0 million and $181.9 million, respectively. Around 45% of Biogen's product revenues are derived from key drugs outside the MS business. Sales of Biogen's spinal muscular atrophy drug, Spinraza, rose in the first quarter due to the favorable timing of shipments in ex-U.S. markets, which is likely to have reversed in the second quarter. In the United States, higher pricing offset the negative impact of a decrease in demand, a trend likely to have continued in the second quarter. The Zacks Consensus Estimate and our estimate for Spinraza are pegged at $397.0 million and $403.0 million, respectively. Though sales of Biogen's newly launched drug Skyclarys for Friedreich's ataxia are likely to have benefited from continued geographic expansion outside the United States, some Medicare discount dynamics might have tempered sequential growth in the United States. Ex-U.S. sales are expected to be a more important driver of growth for Skyclarys in 2025. Another new drug, Zurzuvae's sales are likely to have continued to rise on a sequential basis backed by strong patient demand. Biogen has a collaboration with Sage Therapeutics SAGE for Zurzuvae. Biogen and Sage equally share profits and losses for the commercialization of Zurzuvae in the United States. At the same time, in outside U.S. markets, Biogen records product sales (excluding Japan, Taiwan, and South Korea) and pays royalties to Sage. Zurzuvae has not yet been approved in the EU. Supernus Pharmaceuticals SUPN is acquiring Sage Therapeutics in a deal valued at up to $795 million. Contract manufacturing and royalty revenues and Alzheimer's collaboration revenues are expected to have risen in the quarter. Alzheimer's collaboration revenues include Biogen's 50% share of net product revenues and cost of sales (including royalties) from Alzheimer's drug Leqembi (lecanemab), which has been developed in collaboration with Eisai. Leqembi sales improved sequentially in the last three quarters with the positive trend expected to have continued in the second quarter. Leqembi sales are recorded by Eisai. Leqembi has already been launched in the United States, Japan, China and some other countries. Leqembi was approved in Europe in April 2025 A less frequent maintenance intravenous dosing version of Leqembi was approved by the FDA in January 2025 while a regulatory application for the subcutaneous autoinjector is under review with a decision from the FDA expected on Aug. 31, 2025. BIIB's Earnings Surprise History The company's earnings beat estimates in three of the last four quarters while missing on one. The company has a four-quarter earnings surprise of 8.36%, on average. Biogen's stock has declined 14.0% so far this year against an increase of 3.2% for the industry. Image Source: Zacks Investment Research What Our Model Says for BIIB Our proven model does not conclusively predict an earnings beat for Biogen this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. Earnings ESP: Biogen's Earnings ESP is -0.85%. The Zacks Consensus Estimate is pegged at $3.95 per share, while the Most Accurate Estimate is pegged lower at $3.91 per share. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: Biogen has a Zacks Rank #4 (Sell). Stock to Consider A drug/biotech stock that has the right combination of elements to beat on earnings this time around: Eli Lilly & Company LLY has an Earnings ESP of +1.03% and a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank stocks here. Lilly's stock has risen 5.7% so far this year. LLY beat earnings estimates in two of the last four quarters while missing in the remaining two. On average, Lilly witnessed an earnings surprise of 6.69% in the last four quarters. Lilly is scheduled to release its second-quarter results on Aug. 7. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Supernus Pharmaceuticals, Inc. (SUPN) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Scottish Sun
2 hours ago
- Scottish Sun
Man with dementia dies after accidentally pouring washing detergent in his cup of tea instead of milk
In a similar case two years ago, a dad-of-five died after mistakenly pouring washing detergent on a bowl of cornflakes instead of milk TRAGIC MISTAKE Man with dementia dies after accidentally pouring washing detergent in his cup of tea instead of milk Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) A MAN with dementia died after pouring white-coloured washing detergent into a cup of tea instead of milk in 'an apparent confusion'. David Hayes, 82, from Bolton, accidentally ingested the liquid and was admitted to hospital the next day, on April 16. Sign up for Scottish Sun newsletter Sign up 2 David mistook detergent for milk He had vomited after drinking the tea and is believed to have inhaled the detergent and stomach acid into his lungs causing fatal damage. Doctors diagnosed him with pneumonitis, swelling of the lungs, thought to have been triggered by chemical aspiration. Despite treatment with antibiotics, steroids and pain relief, his condition worsened and he sadly died five days later, on April 21. An inquest held at Bolton Coroner's Court on July 17 concluded his death was accidental. The official cause was pneumonitis and aspiration due to ingestion of a chemical substance. David had Alzheimer's disease, the most common form of dementia which affects memory, thinking skills and other mental abilities. He had previously been discharged from hospital the day before his final admission, following an earlier accidental detergent ingestion. Coroner Michael Pemberton said: 'This had occurred when he had made a cup of tea at home and put washing detergent into the cup instead of milk after an apparent confusion. "He had vomited following the ingestion and it is likely that he aspirated.' Following the inquest, the coroner issued a formal warning to the Government and major charities, urging action to prevent similar deaths. Easy, everyday ways to prevent dementia He wrote to the Department for Environment, Food and Rural Affairs, the Royal Society for the Prevention of Accidents, Age UK, Dementia UK and the Alzheimer's Society, highlighting safety concerns around the packaging of household cleaning products. He said the detergent had been stored in a plastic bottle that resembled a milk carton, with a screw top and no childproof features. This, he said, made it 'easily accessible by a person with reduced capacity or dementia, or even a child'. While the liquid was classed as low toxicity, it still caused vomiting and aspiration in Mr Hayes, ultimately leading to his death. The corner said there was "a risk of similar events". He said this was because "the colouring of the liquid is similar to items which a person suffering from an infirmity such as dementia may get confused - here milk". He also warned that "public knowledge of these risks is not likely to be at a level where households in which vulnerable adults reside are aware of the need to safeguard detergents and make them less accessible." In a similar case two years ago, a dad-of-five died after mistakenly pouring washing detergent on a bowl of cornflakes instead of milk. Tom McDonald died in March 2023. He had been diagnosed with dementia five years earlier. Is it ageing or dementia? Dementia - the most common form of which is Alzheimer's - comes on slowly over time. As the disease progresses, symptoms can become more severe. But at the beginning, the symptoms can be subtle or mistaken for normal memory issues related to ageing. The US National Institute on Aging gives some examples of what is considered normal forgetfulness in old age, and dementia disease. You can refer to these above. For example, it is normal for an ageing person to forget which word to use from time-to-time, but difficulting having conversation would be more indicative of dementia. Katie Puckering, Head of Alzheimer's Research UK's Information Services team, previously told The Sun: 'We quite commonly as humans put our car keys somewhere out of the ordinary and it takes longer for us to find them. 'As you get older, it takes longer for you to recall, or you really have to think; What was I doing? Where was I? What distracted me? Was it that I had to let the dog out? And then you find the keys by the back door. 'That process of retrieving the information is just a bit slower in people as they age. 'In dementia, someone may not be able to recall that information and what they did when they came into the house. 'What may also happen is they might put it somewhere it really doesn't belong. For example, rather than putting the milk back in the fridge, they put the kettle in the fridge.'
Yahoo
2 hours ago
- Yahoo
AI Meets Brain Health: League and Linus Health Collaborate to Expand Health Plan Platforms
Bringing early detection of cognitive impairment to the forefront of health plan CX — empowering personalized, proactive brain health BOSTON and TORONTO, July 28, 2025 /PRNewswire/ -- Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and personalized intervention, is collaborating with League, the leading healthcare consumer experience (CX) platform, to make online cognitive screening and care available to millions of Americans through private health plans. The collaboration was announced today at the Alzheimer's Association International Conference (AAIC) taking place this week in Toronto. Health plan portals powered by League's CX platform can access Linus Health's groundbreaking digital cognitive assessments along with educational content on dementia, brain health, and evidence-based interventions such as lifestyle changes. Also included is access to its ecosystem of care from Alzheimer's disease (AD)-biomarker blood testing to telehealth services and clinical trials. This integration enables plans to embed proactive brain health support directly into their digital front door, enhancing their ability to identify at-risk members earlier, promote cognitive wellness, and scale access to personalized care pathways. "To effectively change the trajectory of Alzheimer's and other dementias, we must first identify individuals who are at risk but often overlooked, and connect them early to the resources that can make a real difference," said David Bates, PhD, CEO and co-founder of Linus Health. "Our collaboration with League will help millions of health plan members access proactive assessments and equip clinicians to intervene sooner—when it matters most." Ninety-two percent of patients with mild cognitive impairment (MCI), a precursor of dementia, go undetected, leaving millions without access to early interventions that can delay or even prevent dementia. MCI detection generally requires an in-person screening by a clinician followed by a multi-hour evaluation by a neuropsychologist, but Linus Health's FDA-listed, AI-powered remote assessment can help detect early signs of MCI before symptoms manifest. "This collaboration offers an opportunity for payers to proactively address the escalating costs and profound impact of cognitive decline," said Michael Serbinis, CEO of League. "By integrating Linus Health's advanced MCI and dementia detection capabilities within League's AI-powered CX platform, we will equip health plans with a scalable solution to identify at-risk members earlier, enable timely interventions, and ultimately drive significant improvements in member outcomes and population health management—while also delivering unprecedented member benefits that will improve millions of lives." Those attending AAIC are invited to visit Linus at booth #1219. For more information about Linus Health, connect with us here. Also, be sure to check out the research Linus Health is presenting at AAIC powered by AI-driven insights across cognition, meaning, motor function, and speech—accelerating study recruitment and enabling more equitable, personalized brain health care. About Linus HealthLinus Health is a Boston-based digital health company focused on transforming brain health for people across the world. By advancing how we detect and address cognitive and brain disorders – leveraging cutting-edge neuroscience, clinical expertise, and artificial intelligence – our goal is to enable a future where people can live longer, happier, and healthier lives with better brain health. Linus Health's digital cognitive assessment platform delivers a proven, practical means of enabling early detection; empowers providers with actionable clinical insights; and supports individuals with personalized action plans. We are proud to partner with leading healthcare delivery organizations, research institutions, and life sciences companies to accelerate more proactive intervention and personalized care in brain health. To learn more about our practical solutions for proactive brain health®, visit or follow us on LinkedIn. About LeagueFounded in 2014, League is the leading healthcare consumer experience platform, reaching more than 40 million people around the world and delivering the highest level of personalization in the industry. Payers, providers, and consumer health partners build on League's platform to deliver high-engagement healthcare solutions proven to improve health outcomes. League has raised over $285 million in venture capital funding to date, powering the digital experiences for some of healthcare's most trusted brands, including Highmark Health, Manulife, Medibank, and SCAN. Media Contact:Tara StultzAmendola Communications for Linus Healthtstultz@ View original content to download multimedia: SOURCE Linus Health
